Enveric Biosciences Inc (NASDAQ:ENVB) — Market Cap & Net Worth
Market Cap & Net Worth: Enveric Biosciences Inc (ENVB)
Enveric Biosciences Inc (NASDAQ:ENVB) has a market capitalization of $710.07K ($710.07K) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30683 globally and #6133 in its home market, demonstrating a -21.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enveric Biosciences Inc's stock price $1.37 by its total outstanding shares 518297 (518.30K). Review ENVB total debt and obligations to assess the company's total debt and financial obligations.
Enveric Biosciences Inc Market Cap History: 2015 to 2026
Enveric Biosciences Inc's market capitalization history from 2015 to 2026. Data shows change from $17.10 Billion to $710.07K (-60.29% CAGR).
Index Memberships
Enveric Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #911 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #2879 of 3165 |
Weight: Enveric Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Enveric Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enveric Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.96x
Enveric Biosciences Inc's market cap is 0.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $17.10 Billion | $15.98 Million | -$1.89 Million | 1070.57x | N/A |
| 2016 | $16.87 Billion | $36.15 Million | -$2.78 Million | 466.74x | N/A |
| 2017 | $8.03 Billion | $48.59 Million | -$9.07 Million | 165.32x | N/A |
| 2018 | $450.92 Million | $43.00 Million | -$16.90 Million | 10.49x | N/A |
| 2019 | $234.27 Million | $39.91 Million | -$5.60 Million | 5.87x | N/A |
| 2020 | $38.35 Million | $39.91 Million | -$6.86 Million | 0.96x | N/A |
Competitor Companies of ENVB by Market Capitalization
Companies near Enveric Biosciences Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Enveric Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Enveric Biosciences Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Enveric Biosciences Inc's market cap moved from $17.10 Billion to $ 710.07K, with a yearly change of -60.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $710.07K | -62.26% |
| 2025 | $1.88 Million | +912.83% |
| 2024 | $185.76K | -72.43% |
| 2023 | $673.79K | -37.50% |
| 2022 | $1.08 Million | -95.53% |
| 2021 | $24.10 Million | -37.16% |
| 2020 | $38.35 Million | -83.63% |
| 2019 | $234.27 Million | -48.05% |
| 2018 | $450.92 Million | -94.39% |
| 2017 | $8.03 Billion | -52.38% |
| 2016 | $16.87 Billion | -1.36% |
| 2015 | $17.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Enveric Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $710.07K USD |
| MoneyControl | $710.07K USD |
| MarketWatch | $710.07K USD |
| marketcap.company | $710.07K USD |
| Reuters | $710.07K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more